Bing Yao, ArriVent BioPharma CEO
January 5, 2024 04:58 PM EST
Financing
Startups

Ar­riVent files for IPO, rais­ing funds as it takes PhI­II can­cer drug through tri­al

Kyle LaHucik

Senior Reporter

Penn­syl­va­nia on­col­o­gy drug­mak­er Ar­riVent Bio­phar­ma has filed for an ini­tial pub­lic of­fer­ing, mak­ing it the sec­ond biotech to re­veal its plans …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times